DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 7,547,546
|Title:||Progenitor cells from wharton\'s jelly of human umbilical cord|
|Abstract:||Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC-/- progenitor cells, and is useful to grow and repair human tissues including bone.|
|Inventor(s):||Davies; John E. (Toronto, CA), Baksh; Dolores (Mississauga, CA), Sarugaser; Rahul (Toronto, CA), Hosseini; Morris (Braunschweig, DE), Lickorish; Antony D. S. (Toronto, CA)|
|Assignee:||Tissue Regeneration Therapeutics Inc. (Toronto, Ontario, CA)|
|Patent Claims:||1. A method of obtaining a population of human umbilical cord perivascular (HUCPV) cells, comprising: (a) obtaining an excised blood vessel from human umbilical cord comprising the
perivascular region of said vessel; and (b) treating said blood vessel by enzymatic digestion of the perivascular region and isolating a population of HUCPV cells that comprise an MHC.sup.-/- phenotype from said digested perivascular region.
2. The method according to claim 1, wherein the enzymatic digestion is performed using collagenase.
3. The method according to claim 2, wherein the enzymatic digestion is performed at 37.degree. C. in phosphate buffered saline and 0.1-10.0 mg/mL collagenase for a period of 1 to 24 hours.
4. The method according to claim 1, further comprising culturing said population of HUCPV cells to expand the population thereof.
5. The method according to claim 1, further comprising cryopreserving the population of HUCPV cells.
6. The method according to claim 4, further comprising cryopreserving the expanded population of HUCPV cells.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Smith And Nephew||SANTYL||collagenase||OINTMENT;TOPICAL||101995||001||1965-06-04||Start Trial||Tissue Regeneration Therapeutics Inc. (Toronto, Ontario, CA)||2023-02-11||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2004072273||Start Trial|
|United States of America||2005148074||Start Trial|
|United States of America||2009269318||Start Trial|
|United States of America||2013259840||Start Trial|
|United States of America||2016032241||Start Trial|
|United States of America||2017157180||Start Trial|
|United States of America||8481311||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.